Alpha Tau Medical ($DRTS): 18 catalysts, 2026–2027 timelines, clinical readouts, FDA milestones, Tolmar, Japan and potential stock impact.

AURORA plays a captivating show, in partnership with War Child, at London's Union Chapel.

Global specialty drugmaker Tolmar marked the grand opening of its new Burlington headquarters this week as the company prepares for its future in Canada

Alpha Tau secures a $35M upfront package from Tolmar, plus up to $161.5M in milestones, for exclusive U.S. prostate cancer rights to its

Tolmar’s Rubraca gains FDA approval for BRCA-mutated prostate cancer before chemotherapy. Explore the trial results and what it means for treatment strategy.

Reported Wednesday, Jun 3 - 9:07am EDT (TheFly subscription required to read more.)

Tolmar Inc. has launched a specialized YouTube channel to empower Advanced Practice Providers in managing testosterone replacement therapy effectively. Discover this new resource.

Tolmar, Inc. has launched Care Partner Corner, a digital platform aimed at supporting caregivers of prostate cancer patients with essential resources.

The FDA has granted expanded approval for Rubraca®, the first PARP inhibitor to outperform docetaxel, offering earlier treatment options for prostate cancer patients.

Rosalind Franklin University has welcomed Tolmar, Inc. to its Innovation and Research Park, enhancing pharmaceutical development opportunities in Illinois.

The Peaks Challenge, launched by ZERO Prostate Cancer and Tolmar, aims to raise awareness about survivorship and early detection of prostate cancer through a groundbreaking climbing expedition.

Alpha Tau (Nasdaq:DRTS) and Tolmar entered a long‑term U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer, with an option for bladder cancer.Tolmar will invest $20M in equity at $11.99 per share, fund $15M for a new U.S. manufacturing facility, and may pay up to $161.5M in development, regulatory and commercial milestones for the initial indication. Alpha Tau will manufacture Alpha DaRT, supplying Tolmar at 60% of net sales, while Tolmar holds exclusive U.S. commercialization rights for prostate cancer for an expected 20‑year term.

Comprehensive website provides education, tools, and emotional support for those caring for loved ones with prostate cancer BUFFALO GROVE, Ill., Feb. 4, 2026 /PRNewswire/ -- Tolmar, Inc. today announced the launch of Care Partner Corner (www.CarePartnerCorner.com), a comprehensive digital...

FDA approval is based on the positive results of TRITON3, a Phase 3, multicenter, open-label, randomized clinical trial of Rubraca® (rucaparib) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients This approval makes rucaparib an earlier treatment option...

9 Survivors. 11 Advocates. One Mountain. A Life-Changing Mission to Save Lives. ALEXANDRIA, Va., June 17, 2025 /PRNewswire/ -- ZERO Prostate Cancer, the nation's leading prostate cancer advocacy and support organization, is proud to announce a bold new initiative—the "Peaks Challenge"...